MarizkiPondawinata (2020) Efek Atorvastatin Terhadap Kadar CETP (Cholesteryl Ester Transfer Protein) Dan Profil Lipid Pada Pasien Anak Sindrom Nefrotik Refrakter Dengan Hiperlipidemia (Penelitian dilaksanakan di Poli Nefrologi Anak RSUD Dr. Soetomo Surabaya). Thesis thesis, UNIVERSITAS AIRLANGGA.

	Text (HALAMAN JUDUL) 1. HALAMAN JUDUL.pdf Download (350kB)
	Text (ABSTRACT) 2. ABSTRACT.pdf Download (58kB)
	Text (DAFTAR ISI) 3. DAFTAR ISI.pdf Download (153kB)
	Text (BAB 1) 4. BAB 1 PENDAHULUAN.pdf Download (49kB)
	Text (BAB 2) 5. BAB 2 TINJAUAN PUSTAKA.pdf Restricted to Registered users only until 15 December 2023. Download (587kB) | Request a copy
	Text (BAB 3) 6. BAB 3 KERANGKA KONSEPTUAL DAN KERANGKA OPERASIONAL.pdf Restricted to Registered users only until 15 December 2023. Download (170kB) | Request a copy
	Text (BAB 4) 7. BAB 4 METODE PENELITIAN.pdf Restricted to Registered users only until 15 December 2023. Download (123kB) | Request a copy
	Text (BAB 5) 8. BAB 5 HASIL PENELITIAN.pdf Restricted to Registered users only until 15 December 2023. Download (150kB) | Request a copy
	Text (BAB 6) 9. BAB 6 PEMBAHASAN.pdf Restricted to Registered users only until 15 December 2023. Download (116kB) | Request a copy
	Text (BAB 7) 10. BAB 7 KESIMPULAN DAN SARAN.pdf Restricted to Registered users only until 15 December 2023. Download (34kB) | Request a copy
	Text (DAFTAR PUSTAKA) 11. DAFTAR PUSTAKA.pdf Download (143kB)
	Text (LAMPIRAN) 12. LAMPIRAN.pdf Restricted to Registered users only until 15 December 2023. Download (549kB) | Request a copy
	Text (EMBARGO) 13-Embargo Marizki Pondawinata.pdf Restricted to Registered users only Download (165kB) | Request a copy

Abstract

BACKGROUND – Atorvastatin is one of the statin drugs recommended for treatinghyperlipidemia inchildren because it is more potent and safer with minimal drug side effects.Various studies have found the effect of atorvastatin on CETP level, but the results obtainedare still controversial.OBJECTIVE – To analyze the effect of atorvastatin on CETP level and lipid profiles inchildren refractory nephrotic syndrome with hyperlipidemia.METHOD – A randomized clinical trial (RCT), double blind, pre and post test control groupwith treatment given for 4 weeks. The research group consisted of two groups: the controlgroup (placebo/without atorvastatin) and the treatment group (atorvastatin). The study wasconducted in pediatric nephrological outpatients Dr. Soetomo Surabaya from December2019 to March 2020. Initial examination was carried out at week 0 ie complete blood,urinalysis, albumin, BUN, serum creatinine, liver function, total cholesterol, LDL, HDL,TG, and CETP. After 4 weeks, the examination was retested.RESULTS AND CONCLUSIONS – From the results, the difference in average totalcholesterol and LDL at week 0 and week 4 in the control group and the treatment group wassignificant (p <0.05). Giving atorvastatin reduced total cholesterol by 29.2%, LDLcholesterol by 30.8%, TG level by 7.5%, and did not yet have an increase in HDL cholesterollevels. In this study, the mean CETP level in the treatment group were not significantdifferences despite a decrease in CETP level of 8%. Patients receiving atorvastatin showeda relationship between changes in CETP level with total cholesterol and LDL level. Thus,CETP can be said to be a new biomarker candidate of hyperlipidemia in pediatric patientswith refractory nephrotic syndrome.

Actions (login required)

View Item